Tibolone vaginal versus per os administration in the management of post-menopausal symptoms

 
This item is provided by the institution :
Technological Educational Institute of Athens
Repository :
Ypatia - Institutional Repository
see the original item page
in the repository's web site and access all digital files if the item*
share




2009 (EN)
Tibolone vaginal versus per os administration in the management of post-menopausal symptoms (EN)

Γαλάζιος, Γεώργιος (EL)
Ζερβούδης, Στέφανος (EL)
Ιατράκης, Γεώργιος Μ. (EL)
Τσίκουρας, Παναγιώτης (EL)
Πεϊτσίδης, Παναγιώτης (EL)

Λυμπέρης, Βασίλειος (EL)
Σχολή Επαγγελμάτων Υγείας και Πρόνοιας. Τμήμα Μαιευτικής (EL)
Ναυρόζογλου, Ιορδάνης (EL)
Badiu, C. (EN)
Ceauşu, I. (FR)

Tibolone is a selective tissue estrogenic activity regulator effective in the management of climacteric symptoms, without stimulating endometrial and breast tissue proliferation. It is a well-tolerated treatment regimen with minor adverse effects. The purpose of the current trial was to investigate the efficacy of tibolone administration per os versus per vaginal, concerning the treatment of climacteric symptoms. MATERIAL AND METHOD: A total of 64 post-menopausal healthy women aged 44-55 years (mean 52,5) were enrolled in the study. The patients were divided into three groups: Group A with 24 patients receiving per os Tibolone 2.5 mg x 1 daily for 6 months, Group B with 21 patients receiving vaginally Tibolone 2.5 mg x 1 for 6 months and Group C--with 19 patients receiving only hygienodietetics advices and psychological support for 6 months. All subjects underwent a physical examination, including a transvaginal ultrasonography for the measurement of endometrial thickness and a mammography for the assessment of breast density. RESULTS: In Group A and B, climacteric symptoms were similarly reduced with non significant differences between groups: 79% (19 patients) vs 76% (16 patients) reduction for hot flushes and 83% (20 patients) vs 76% (16 patients) for sweating episodes respectively (p > 0.05). Reduction of hot flushes and sweating episodes was observed in only 2 of 19 patients (10.5%) in group C (p < 0.01). Vaginal route had better results on vaginal dryness-dyspareunia in group B (in 14 patients taken tibolone orally-58% vs 16 patients taken tibolone vaginally-76%). No statistically significant difference was found related to urine symptoms between A and B groups. Tibolone by vaginal route did not cause any severe side effects (apart of a slight discharge) and it was equally (or better) tolerated than oral route. No significant alterations in breast density and BIRADS and no increase in endometrial thickness were observed in all study groups. CONCLUSION: Tibolone is effective in relieving climacteric symptoms indifferent from applications-modus: orally or vaginally. However, further and larger studies are required to confirm results. (EN)

journalArticle

Διατροφή (EN)
Ψυχολογική υποστήριξη (EN)
Nutrition (EN)
Στεροειδής ορμόνες, Θεραπευτικές ιδιότητες (EN)
Steroid hormones--Therapeutic use (EN)
Psychological support (EN)

ΤΕΙ Αθήνας (EL)
Technological Educational Institute of Athens (EN)

Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi (EN)

English

2009


US National Library of Medicine (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)